Drugs / CTP-692
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03880253 | Apr → May 2019 | — | Concert Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03830463 | Jan → Mar 2019 | — | Concert Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT03778320 | Dec 2018 | — | Concert Pharmaceuticals | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04158687 | Nov 2019 → Dec 2020 | schizophrenia | Concert Pharmaceuticals | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTP-692 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03880253 ↗ |
| Route | Oral | “Single oral dose” NCT03778320 ↗ |